Cargando…

MHC-I genotype and tumor mutational burden predict response to immunotherapy

BACKGROUND: Immune checkpoint blockade (ICB) with antibodies inhibiting cytotoxic T lymphocyte-associated protein-4 (CTLA-4) and programmed cell death protein-1 (PD-1) (or its ligand (PD-L1)) can stimulate immune responses against cancer and have revolutionized the treatment of tumors. The influence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goodman, Aaron M., Castro, Andrea, Pyke, Rachel Marty, Okamura, Ryosuke, Kato, Shumei, Riviere, Paul, Frampton, Garrett, Sokol, Ethan, Zhang, Xinlian, Ball, Edward D., Carter, Hannah, Kurzrock, Razelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236948/ https://www.ncbi.nlm.nih.gov/pubmed/32430031 http://dx.doi.org/10.1186/s13073-020-00743-4

Ejemplares similares

Tumor mutational burden is not predictive of cytotoxic chemotherapy response
por: Nikanjam, Mina, et al.
Publicado: (2020)

SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
por: Botta, Gregory P., et al.
Publicado: (2021)

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
por: Okamura, Ryosuke, et al.
Publicado: (2020)

Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers
por: Pham, Timothy V., et al.
Publicado: (2021)

Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy
por: Pham, Timothy V., et al.
Publicado: (2020)

Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy
por: Krishnamurthy, Nithya, et al.
Publicado: (2022)

Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease
por: Cohen, Philip R., et al.
Publicado: (2017)

Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden
por: Bieg‐Bourne, Cheyennedra C., et al.
Publicado: (2020)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real‐world precision‐medicine population
por: Rosenberg, Shai, et al.
Publicado: (2023)

Autoimmune HLA Alleles and Neoepitope Presentation Predict Post-Allogenic Transplant Relapse
por: Castro, Andrea, et al.
Publicado: (2023)

Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies
por: Goodman, Aaron M., et al.
Publicado: (2017)

APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy
por: Boichard, Amélie, et al.
Publicado: (2018)

Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary
por: Kato, Shumei, et al.
Publicado: (2021)

Liquid biopsy: current technology and clinical applications
por: Nikanjam, Mina, et al.
Publicado: (2022)

Of Mice, Not Men: When the Bench-to-Bedside Bridge Is Broken
por: Nikanjam, Mina, et al.
Publicado: (2022)

Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy
por: Louie, Bryan H., et al.
Publicado: (2022)

Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy
por: Cohen, Philip R, et al.
Publicado: (2020)

Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer
por: Patel, Hitendra, et al.
Publicado: (2019)

Targeting G(1)/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor–based regimens
por: Kato, Shumei, et al.
Publicado: (2021)

High prevalence of clonal hematopoiesis‐type genomic abnormalities in cell‐free DNA in invasive gliomas after treatment
por: Okamura, Ryosuke, et al.
Publicado: (2021)

Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies
por: Gupta, Diviya, et al.
Publicado: (2022)

Precision medicine‐based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience
por: Louie, Bryan H., et al.
Publicado: (2022)

Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience
por: Bohan, Sandy S., et al.
Publicado: (2020)

Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers
por: Okamura, Ryosuke, et al.
Publicado: (2020)

Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach
por: Kato, Shumei, et al.
Publicado: (2017)

Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench
por: Subbiah, Vivek, et al.
Publicado: (2022)

Total Number of Alterations in Liquid Biopsies Is an Independent Predictor of Survival in Patients With Advanced Cancers
por: Vu, Peter, et al.
Publicado: (2020)

The Conundrum of Genetic “Drivers” in Benign Conditions
por: Kato, Shumei, et al.
Publicado: (2016)

MHC-I genotype drives early immune selection of oncogenic mutations
por: Marty, Rachel, et al.
Publicado: (2018)

The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match
por: Subbiah, Vivek, et al.
Publicado: (2018)

Relationship between tumor mutational burden and maximum standardized uptake value in 2-[(18)F]FDG PET (positron emission tomography) scan in cancer patients
por: Haghighat Jahromi, Amin, et al.
Publicado: (2020)

The paradox of cancer genes in non-malignant conditions: implications for precision medicine
por: Adashek, Jacob J., et al.
Publicado: (2020)

Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies
por: Shayeb, Akram Mesleh, et al.
Publicado: (2023)

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity
por: Kato, Shumei, et al.
Publicado: (2020)

Cancer immunity marker RNA expression levels across gynecologic cancers: Implications for immunotherapy
por: Jou, Jessica, et al.
Publicado: (2023)

Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival
por: Kato, Shumei, et al.
Publicado: (2019)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Genomic landscape of salivary gland tumors
por: Kato, Shumei, et al.
Publicado: (2015)

Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients
por: Charo, Lindsey M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n065dlvgksqa2a4nica3pdmvo1